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**Background:** Precision medicine utilizing genetic testing has recently received much attention given that the variability of response and tolerability to psychotropic medications are partly due to an individual's genetic variations. This has led to increasing research to investigate the role of specific genetic factors on psychotropic medication response and utility of testing in the clinical realm (Zai et al., 2014, Pharmacogenomics, 15, 1147--1157). Antidepressant medications are the first-line pharmacological treatment for mood, anxiety, and obsessive-compulsive and related disorders. However, 20--50% of patients show poor or minimal response to these medications.

**Purpose:** We aimed to investigate the genetics of antidepressant response in patients with obsessive-compulsive disorder (OCD) in two ethnic groups.

**Hypothesis:** We postulated that different genetic variations across known OCD candidate genes may predict antidepressant response in OCD patients with different ethnic background.

**Method:** We examined two independent and ethnically different OCD samples. The Canadian sample comprises of 222 Caucasian OCD subjects and we investigated 32 single nucleotide polymorphisms (SNPs) across 14 OCD candidate genes and their regulatory regions with antidepressant response data using a custom-made 32-SNP QuantStudio Flex Real-Time PCR System Chip. Individuals were grouped into those who improved following an adequate trial of antidepressant as compared with those who reported "minimal" improvement, "no change", or "worsening" using the Clinical Global Impression -- Improvement scale. Pearson χ^2^ test was performed to detect differences in the number of responders versus non-responders across genotype groups. The Brazilian sample consists of 192 Brazilian OCD individuals and 45 SNPs across 18 OCD candidate genes were genotyped. Of the 192 Brazilian OCD participants, 74 completed an adequate antidepressant trial and change of the Yale-Brown Obsessive-Compulsive Scale severity scores pre- and post-treatment were compared between genotype distributions of each examined SNP.

**Results:** For the Canadian sample, interesting associations (*P*\<0.05) were detected for the serotonin genes, *HTR2A* and *HTR1B* in antidepressant response. For the Brazilian sample, significant associations were detected for a gabaergic system gene, *GABRA3*, and antidepressant response (*P*\<0.05).

**Conclusions:** These variants may be clinically useful in predicting treatment resistance versus response in patients with OCD, thereby, reducing their duration of suffering via trial-and-error method of prescribing and improving clinical outcome.
